Medpace Holdings, Inc. (MEDP) Net Income
The trailing-twelve-month (TTM) net income for Medpace Holdings, Inc. (MEDP) is $460.40 Million with a year-over-year change of +10.57%. Net income represents the company's bottom line profit after all expenses, taxes, and interest.
MEDP Annual Net Income
Net Income (TTM)
$460.40M
$460.40 Million
Year-over-Year Change
+10.57%
vs. $416.39M a year ago (TTM)
Net Income CAGR
+23.58%
5 Year compound annual growth rate
Net Income CAGR (Compound Annual Growth Rate)
1 Year
+10.57%
3 Year
+21.45%
5 Year
+23.58%
10 Year
+27.33%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
Annual Net Income History
| Year | Net Income | YoY Change | % Change |
|---|---|---|---|
| 2025 | $451.12M | +$46.74M | +11.56% |
| 2024 | $404.39M | +$121.58M | +42.99% |
| 2023 | $282.81M | +$37.44M | +15.26% |
| 2022 | $245.37M | +$63.52M | +34.93% |
| 2021 | $181.85M | +$36.46M | +25.08% |
| 2020 | $145.38M | +$44.94M | +44.74% |
| 2019 | $100.44M | +$27.26M | +37.25% |
| 2018 | $73.19M | +$34.06M | +87.07% |
| 2017 | $39.12M | +$25.70M | +191.41% |
| 2016 | $13.43M | +$22.10M | — |
Net Income Growth Summary
TTM Growth
+10.57%
3-Year Avg Growth
+21.45%
5-Year Avg Growth
+23.58%
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle